Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 3 | 4 |
| 2005 | 5 | 2 | 7 |
| 2006 | 5 | 8 | 13 |
| 2007 | 5 | 6 | 11 |
| 2008 | 7 | 7 | 14 |
| 2009 | 10 | 5 | 15 |
| 2010 | 16 | 15 | 31 |
| 2011 | 12 | 10 | 22 |
| 2012 | 22 | 8 | 30 |
| 2013 | 23 | 8 | 31 |
| 2014 | 15 | 9 | 24 |
| 2015 | 15 | 16 | 31 |
| 2016 | 15 | 9 | 24 |
| 2017 | 10 | 15 | 25 |
| 2018 | 14 | 11 | 25 |
| 2019 | 12 | 11 | 23 |
| 2020 | 5 | 11 | 16 |
| 2021 | 13 | 9 | 22 |
| 2022 | 2 | 11 | 13 |
| 2023 | 0 | 10 | 10 |
| 2024 | 1 | 9 | 10 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. Cell Rep Med. 2025 Mar 18; 6(3):101983.
-
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024 Dec 05; 26(12):2316-2327.
-
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024 Oct 21; 83(11):1561-1571.
-
A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors. Neuro Oncol. 2024 Oct 03; 26(10):1895-1911.
-
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
-
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024 Dec; 99(12):2388-2391.
-
Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1ß Secretion and T Cell Adjuvanticity. J Med Chem. 2024 Sep 12; 67(17):14974-14985.
-
PIKfyve, expressed by CD11c-positive cells, controls tumor immunity. Nat Commun. 2024 Jun 28; 15(1):5487.
-
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol. 2025 Jan; 43(1):63-75.
-
An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer. JCO Oncol Pract. 2024 Jul; 20(7):899-906.